New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 25, 2014
09:11 EDTBKW, ADXS, QIHU, X, TRP, INSY, RGDO, RHHBY, ITMN, THI, MRKOn The Fly: Pre-market Movers
HIGHER: Burger King (BKW), up 13% after confirming talks regarding a potential strategic transaction with Tim Hortons (THI). Shares of the Canadian donut shop operator trading in New York are also up 17%... InterMune (ITMN), up 36% after Roche (RHHBY) agreed to acquire the company for $74.00 per share... Advaxis (ADXS), up 4% after entering clinical trial collaboration agreement with Merck (MRK)... Insys Therapeutics (INSY), up 5.5% after receiving FDA orphan drug designation for CBD... TransCanada (TRP), up 2.2% after Barron's says the company could climb 35%... U.S. Steel (X), up 3.7% after upgraded at Credit Suisse. LOWER: Regado (RGDO), down 52% after the company terminated enrollment in its REGULATE-PCI Phase 3 trial... Qihoo 360 (QIHU), down 5% after reporting Q2 earnings, Q3 outlook.
News For BKW;THI;ITMN;RHHBY;RGDO;INSY;TRP;X;QIHU;ADXS;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 17, 2014
08:48 EDTXBofA/Merrill global steel analysts hold analyst/industry conference call
Subscribe for More Information
07:58 EDTMRKDeutsche Bank specialty pharma analyst holds analyst/industry conference call
Specialty Pharmaceuticals Analyst Gilbert provides of preview of The Improved Reduction of Outcomes: Vytorin Efficacy Internal Study (IMPROVE-IT) on an Analyst/Industry conference call to be held on October 17 at 10 am.
October 16, 2014
14:47 EDTRHHBYRoche in pact with Pharmacyclics to evaluate Imbruvica, Gazyva combo
Subscribe for More Information
13:13 EDTRHHBYRoche considers submitting Ebola test for emergency use approval, WSJ says
Subscribe for More Information
09:35 EDTRHHBYDiplomat announces contract to distribute Esbriet
Subscribe for More Information
09:02 EDTINSYInsys Therapeutics weakness creates buying opportunity, says JMP Securities
Subscribe for More Information
05:58 EDTRHHBYRoche sees FY14 core EPS targeted to grow ahead of sales
Subscribe for More Information
05:56 EDTRHHBYRoche reports 9 month revenue CHF34.76B vs. CHF34.87B last year
Roche CEO Severin Schwan said: “Demand for our products is strong in both divisions and we are well on track to reach our full-year targets. We have had positive news from our product pipeline, including study results for Perjeta in breast cancer and a new combination therapy with Zelboraf in melanoma. The InterMune acquisition has also strengthened our portfolio with a new medicine, Esbriet for idiopathic pulmonary fibrosis, which has now been approved by the FDA. In Diagnostics, growth continues to be driven by the immunodiagnostics business and we have strengthened our molecular diagnostics portfolio with a new generation of testing systems.”
October 15, 2014
18:26 EDTINSYOn The Fly: After Hours Movers
Subscribe for More Information
16:34 EDTINSYInsys Therapeutics receives DEA approval to produce pharmaceutical Cannabidiol
Insys Therapeutics announced that its FDA inspected and Drug Enforcement Agency approved facility in Round Rock, Texas, has received DEA approval to manufacture synthetically its pharmaceutical grade Cannabidiol. The company has also been granted a quota to produce 15kg of CBD in 2014 and expects a larger quota in 2015 for its continued clinical studies. Insys believes these quantities are sufficient to pursue its CBD development program as currently planned. Insys held a pre-IND meeting with the FDA in September 2014 regarding its development program for CBD in pediatric patients suffering from Dravet Syndrome and Lennox-Gastaut Syndrome, two rare forms of pediatric epilepsy. Insys projects to file an IND in December 2014 for these indications. Babich also noted that Insys has compared its pharmaceutical CBD, which is synthetically produced, with plant-derived CBD obtained from the National Institute on Drug Abuse (NIDA), and found both materials contain an identical chemical structure. "We are pleased that testing in our laboratories has confirmed our long-standing belief that our pharmaceutical CBD is the chemical structure of plant-derived CBD and we believe our purity levels will provide consistent material in the clinical programs," Babich concluded.
16:31 EDTINSYInsys Therapeutics provides update on Dronabinol Oral Solution NDA
Subscribe for More Information
15:45 EDTRHHBYFDA approves Esbriet to treat idiopathic pulmonary fibrosis
Subscribe for More Information
14:41 EDTXMissouri AG Chris Koster announces $266K settlement with U.S. Steel
Subscribe for More Information
12:42 EDTMRKNY AG announces $31M Medicaid settlement with Organon
Subscribe for More Information
09:57 EDTMRKLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:53 EDTQIHUQihoo targets 10% share of China mobile search this year, Marbridge Daily says
Subscribe for More Information
07:36 EDTADXSAdvaxis provides clinical update for Phase 1/2 trial of ADXS-HPV candidate
Subscribe for More Information
October 14, 2014
11:23 EDTMRK, RHHBYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
08:06 EDTQIHUQihoo 360 launches ad exchange platform, Marbridge Daily reports
Subscribe for More Information
07:37 EDTMRKAmerican Society of Anesthesiologists to hold annual meeting
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use